Immunostaining of biopsied skeletal muscle of 4 Duchenne (DMD), 12 Becker muscular dystrophy (BMD)and 3 DMDcarriers' was performed using monoclonal antibodies against dystrophin and utrophin. In DMD, dystrophin-negative staining was observed except for revertant fibers which showed different stain patterns for each antibody. In 7 BMDs,there was faint/patchy stain in cases of deletion between exons 45-52, while in one case there was deletion between exons 12-17 and no stain was noted relevant to the deletion site. Moreover, in 2 cases of undetectable deletion, antibodies which recognize a terminal portion of the C-terminal domain revealed the absent stain. In DMD, the utrophin-positive fibers corresponded to dystrophin-negative fibers. In BMD,this relationship did not necessarily occur in each fiber. In DMDcarriers, a cluster of dystrophin-negative fibers which was positive for utrophin were prominent. In dystrophinopathy, the immunostaining of dystrophin and utrophin is useful, in combination with dystrophin gene analysis to makea definite diagnosis. (Internal Medicine 33: 277-283, 1994) 
Introduction
Duchenne (DMD) and Becker muscular dystrophy (BMD) are allied neuromuscular disorders with sex-linked recessive trait caused by an abnormality of dystrophin, a muscle cytoskeletal protein (1) with a molecular mass (MM)of dystrophin -420 kDa. The abnormality appears in the size and/ or relative abundance (2-6) of dystrophin; thus, dystrophin in DMDis deficient, and dystrophin in many patients with BMD consists ofa smaller MM.But it has been reported that dystrophin in the majority ofBMDis detectable on SDS-PAGEas a single smallerMM (2) , or as two different MMs (4, 6) consisting of the dystrophin -390 kDa and -230 kDa. Utrophin (DRP), originally discovered in the process of cloning dystrophin, is one of the dystrophin-related-peptides with MM-395 kDa which is encoded in the chromosome 6q24 and a cytoskeletal protein with homology of 80% at the C-terminal of dystrophin (7) . We performed specific immunostaining analyses of biopsied skeletal muscle in DMD, BMDand definite carriers of DMDusing poly-and monoclonal antibodies (pAb and mAb, respectively) against dystrophin and utrophin.
Materials and Methods
Frozen biopsied muscle samples were obtained with appropriate informed consent from 19 patients (4 DMDs, 3 definite between 321th and 494th), were purchased from Novocastra Laboratories Ltd., Newcastle, UK. Anti-utrophin (DRP) pAb was donated by Dr. Ishiura of Tokyo University, and the mAbwas purchased from Novocastra Laboratories Ltd. These anti-utrophin antibodies had no crossreactivity to dystrophin.
Routine histopathology and histochemistry offrozen sections Hematoxylin and eosin stain, modified Gomoritrichrome method, and stains of NADH-TR, succinic dehydrogenase, routine-myosin ATPase, cytochrome c oxidase, desmin, and developing myosin heavy chain were performed by the conventional methods.
Immunosta ining Frozen sections were preincubated in phosphate-buffered saline (PBS) containing 1 % normal horse serum, washed once in PBSand then incubated with the anti-dystrophin mAbsand anti-utrophin antibodies finally diluted in PB S (anti-dystrophin pAb & mAbs 60kDa 1:200; Dysl 1:500; Dys2 1:5,000; Dys3 1:2,000; 2-5E2 1:4,000; 4-4C5 1:5,000; anti-utrophin pAb 1:200, mAb 1:20,000) overnight in a cold room (4°C). Afterwards, sections were rinsed three times and gently blotted onto filter paper. In order to detect dystrophin-anti-dystrophin immunecomplexes, affinity-purified horse anti-mouse IgG and goat anti-rabbit IgG conjugated to avidin-DH biotinylated horseradish peroxidase (ABCmethod) were applied, and then rinsed three times in PBS. Sections were mountedin Vectastain. The control staining was performed using conventional methods including application of non-immuneserum without antibodies. In addition, biopsied muscles of patients without detectable neuromusculardiseases were used for the negative and positive controls. All stained sections were observed, and were photographed by Nikon light microscopy (Nikon, Tokyo, Japan).
Results
Routine histopathology and histochemistry The numberof muscle fibers was relatively well preserved.
Hypertrophic and splitting fibers , moderately increased internal nuclei and large opaque fibers were observed in DMD and BMD, and were consistent with the myopathic change of dystrophinopathy. By NADH-TR, an oxidative enzyme activity which was characterized by mottled appearance, was noted. Cytochrome c oxidase-negative fibers were not significantly increased.
Connective tissue elements were increased in peri-and endomysium.
Immunostaining DMD
Immunostaining of anti-dystrophin antibodies is shown in Fig. 3 . Utrophin (DRP) stain in serial biopsied muscle sections ofDMD, BMDand DMDcarrier. In DMD4 (upperpanel), utrophin (DRP) is stained except for a revertant fiber (asterisk). In BMD1 1 (middle panel), utrophin (DRP) stain is patchy except for strongly positive utrophin stain in a cluster of regenerating fibers (arrow at left). Desmin-positive fibers are regenerating (arrow at right). In DMDcarrier 1 (lower panel), a cluster of dystrophinnegative fibers were strongly positive utrophin (DRP)stained (Original mag. x200). Staining of all antibodies used here was totally deficient. Very few dystrophin-positive fiber clusters { ' so called' revertant fibers (10)} appeared between 0.1 to 0.7% of fibers examined under random fields. In revertant fibers, staining differences betweenantibodies werenoted in each case and in each fiber (Table 1) . Revertant positive fibers to Dysl, which recognizes the central portion of the rod domain were muchless frequent, while those positive to Dys2, which recognizes the C-terminal portion, were more common (Fig. 1) . Immunostaining of anti-utrophin antibodies is shown in Fig.   3 .
All fibers were fairly well stained, but regenerating fibers with a smaller diameter, which were desmin-positive, were morestrongly stained.
DMDCarriers
Negative fibers against anti-dystrophin antibodies were frequently present in clusters (Fig. 3) . The number of dystrophinnegative fibers seemed to gradually decrease by age. Relationships between negative and positive reactions against anti-dystrophin and anti-utrophin antibodies were noted in most fibers.
BMD
Results of immunostaining of anti-dystrophin antibodies is shown in Table 2 . In 7 BMDpatients with deletions between exons 45 and 52 (major hot spot), the staining showed a faint/ patchy pattern by a pAb and all mAbs examined (Fig. 4) . In one BMDpatient with a deletion between exons 12 and 17 (minor hot spot), the staining showed the total absence in Dys3 and 2-5E2, which are relevant to a deleted portion ofdystrophin gene, instead offairly preserved faint/patchy patterns as seen in 60 kDa, Dysl, 4-4C5 and Dys2 (Fig. 4) .
In 4 patients with no detectable deleted dystrophin gene, the staining patterns were subdivided into two groups, two patients showing a faint/patchy pattern in a pAb and all mAbs, and the other two siblings exhibiting the absent pattern in 4-4C5 and Dys2, instead of the faint/patchy pattern in 60 kDa, Dys3, 2-5E2 and Dysl (Fig. 4) .
Immunostaining of anti-utrophin antibodies was positive in regenerating fibers and in a few non-regenerating dystrophinnegative fibers in some cases (Fig. 3) .
Discussion
DMD and BMD are allied disorders of a dystrophin abnormality, dystrophinopathy. The precise function of dystrophin remains controversial, but it is knownto have a calcium-related mechanism,because of its localization on the surface membranes of the following two systemic tissues: 1 ) contractile cells such as skeletal, cardiac and smooth muscle cells and myoepithelial cells; and 2) neurons and synapses. On the other hand, it is also reported that functional dystrophin contributes to stability based on experiments using hypo-osmotic shock to determine stress resistance and a mousemodel (mdx) for human disease (1 1). Abnormality in dystrophinopathy becomes manifest in the size and/or relative abundance (2-6) of dystrophin; thus, dystrophin in DMDis deficient, while dystrophin in many patients with BMDcan be observed in less abundance, mostly with a smaller molecular mass. In addition, it has been pointed out that dystrophin in the majority (80%) of BMDcan be detected as a single smaller molecular mass (2), or sometimes as two different molecular masses (4, 6) consisting of-390 kDa and-230 kDa.
The immunostaining of mAbsand pAb of dystrophin has showna negative pattern in DMD except for the "so-called" revertant fibers (8) . On immunostaining ofDMD, the dystrophin staining pattern was consistent with that in the previous reports ( 1 2), but the fiber to fiber differing patterns in revertant fibers of DMD probably means that a new conversion (new mutation)
from an out-frame deletion to an in-frame deletion might occur differently in each revertant fiber. Utrophin in DMDwas thought to provide a mechanismfor functional membrane support closely related to dystrophin deficiency. On immunostaining of DMDcarriers, the number of negative fibers in anti-dystrophin antibodies gradually decreased . In BMD1 with a deletion at the major hot spot (exons 45-49), the reaction of all monoclonal antidystrophin antibodies discloses a faint/patchy pattern. In BMD2 with a deletion at the minor hot spot (exons 12-17), the antibody (N-terminal portion) relevant to deletion was devoid of the reaction. In BMD1 2 without detectable deletion, the reaction is negative against monoclonal antibodies at the Cterminal portion.
with age. This finding may indicate that fibers deficient in dystrophin are lost with aging, or that normal dystrophin is supplied from the dystrophin-positive fibers. In addition, the fact that negative and/or positive reactions of dystrophin or utrophin did not always correspond might be simply independent of dystrophin or utrophin genes. On immunostaining of 7 BMDusing 5 mAbs and 1 pAb recognizing through the N-to C-terminal domains , faint/patchy immunostaining was noted in all patients with a deletion at the major hot spot region between exons 45 and 52. The data in these cases indicate that both molecular terminals of dystrophin were probably preserved less abundantly. In one patient with deletion at the minor hot spot region between exons 12 and 17, the immunostaining of dystrophin was totally devoid of reaction for two mAbs (2-5E2 and Dys3) which recognize the upstream region of the rod domain, and are relevant to the deletion site between exons 12 and 17. In 4 BMD patients without detectable deletion, two immunostaining patterns of dystrophin were observed; two cases faint/patchy in pAb and all mAbs and the other 2 cases deficient in 2 mAbs (4-4C5 and Dys2). The mAbs 4-4C5 and Dys2 recognize the very terminal portion of C-terminal domain. Recently, it was reported that a defect of either cysteinerich domain or a part of C-terminal domain binding dystrophinassociated glycoprotein (DAP) causes serious illness (13) . Therefore, it is thought that the latter siblings might have a smaller deletion or the nucleotide substitution within the Cterminal domain except for the DAPbinding site. On the other hand, their muscle weakness was mild in spite of the association with mental retardation and juvenile diabetes mellitus. Their immunostaining pattern suggests that the tissue distribution of abnormal dystrophin was different from organ to organ, since muscle weaknesswas mild comparedwith the other clinical features (mental deficiency and diabetes mellitus). In utrophin staining of BMD, the regenerating fibers were strongly positive. This fact implies that utrophin appears at the early developing stage of muscle fiber, and gradually disappears with development ofdystrophin. In conclusion, dystrophin is the most important sarcolemmal protein. When it is totally or partially absent in DMD,DMDcarriers and BMD,then utrophin, one of the membrane constituents, mayplay an essential role in compensating for the dystrophin deficiency.
